Section Arrow
Quote
BMRN.NASDAQ
- BioMarin Pharmaceutical
Quotes are at least 15-min delayed:2026/07/09 01:24 EDT
Regular Hours
Last
 59.75
-0.6 (-0.99%)
Day High 
60.67 
Prev. Close
60.35 
1-M High
60.541 
Volume 
1.55M 
Bid
55
Ask
61
Day Low
59.63 
Open
59.88 
1-M Low
54.26 
Market Cap 
11.66B 
Currency 美元 
P/E 43.42 
%Yield -- 
10-SMA 58.1 
20-SMA 56.98 
50-SMA 54.94 
52-W High 66.275 
52-W Low 49.2592 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
1.39/6.51
Enterprise Value
12.26B
Balance Sheet
Book Value Per Share
32.14
Cash Flow
Cash Flow Yield
0.07
Income Statement
Total Revenue
3.22B
Operating Revenue Per Share
11.95
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TVRDTvardi Therapeutics Inc5+1.9+61.29%-- 
RXRXRecursion Pharmaceuticals3.72-0.12-3.13%-- 
CRNXCrinetics Pharmaceuticals83.49-0.04-0.05%-- 
GOSSGossamer Bio0.169-0.0085-4.79%-- 
SLSSELLAS Life Sciences Group13.76+0.26+1.93%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.